Clinical trials: Polymorphous Light Eruption
Polymorphic Light Eruption (PLE)
Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)
The purpose of this study is to determine whether the afamelanotide (CUV1647) formulation is effective in preventing PLE episodes or reducing the severity of PLE symptoms in patients with a well documented history of the disease.
- Trial name
- NCT00472901
- Testing
- Afamelanotide (CUV1647)
- Where
- 3 sites in Australia, Austria and 1 more
- Volunteers
- 18 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Polymorphic Light Eruption
Calcipotriol and Polymorphic Light Eruption
Polymorphic light eruption (PLE) is a photodermatosis with an extremely high prevalence, particularly among young women (up to 20%).
- Trial name
- NCT00871052
- Testing
- Calcipotriol-containing cream
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- Medical University of Graz
Psoriasis, Alopecia Areata
Improving Disease Severity
Phototherapy, including ultraviolet B (UVB) and ultraviolet A (UVA) light, has been used to treat a number of dermatologic conditions.
- Conditions
- Psoriasis, Alopecia Areata, Polymorphous Light Eruption
- Trial name
- NCT05391178
- Testing
- Lumiton yarn sleeve, Lumiton yarn hat, Lumiton yarn shirt
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Wake Forest University Health Sciences
Polymorphic Light Eruption, Psoriasis
Regulatory T Cells (Tregs) in Polymorphic Light Eruption
Polymorphic light eruption (PLE) is a photodermatosis with an extremely high prevalence, particularly among young women (up to 20%).
- Conditions
- Polymorphic Light Eruption, Psoriasis, Atopic Eczema
- Trial name
- NCT00555178
- Where
- 2 sites in Austria
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Polymorphic Light Eruption
Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)
This study was to evaluate the safety and efficacy of afamelanotide in patients suffering from polymorphic light eruption (PLE).
- Trial name
- NCT04704713
- Testing
- Afamelanotide
- Volunteers
- 31 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Polymorphic Light Eruption
Skin Microbiome and Polymorphic Light Eruption
Polymorphic light eruption (PLE) is the most common form among UV-inducible disorders with a prevalence of approximately 11-21% worldwide and a clear predisposition of women.
- Trial name
- PLE_microbio (NCT04985526)
- Testing
- Octeniderm (octenidine dihydrochloride, 1-propanol, 2- propanol)
- Where
- Austria
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Psoriasis, Cutaneous T Cell Lymphoma
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
The molecular mechanisms of action of photo(chemo)therapy in skin diseases are investigated in this study. The phototherapeutic modalities employed include UVB (ultraviolet B), UVA (ultraviolet A), PUVA (psoralen+UVA) and/or…
- Conditions
- Psoriasis, Cutaneous T Cell Lymphoma, Lymphoproliferative Disorders, Eczema
- Trial name
- BioUV2017 (NCT03340155)
- Testing
- Photo(chemo)therapy
- Where
- Austria
- Volunteers
- 240 people
- Sponsor
- Medical University of Graz
Polymorphic Light Eruption
Sunscreen and After-sun-lotion Protection in Polymorphic Light Eruption
Polymorphic light eruption (PLE) is a common photodermatosis characterized by the appearance of itching, erythema, papules or vesicles on sun-exposed skin.
- Trial name
- NCT00549588
- Testing
- After-sun-lotion with DNA repair enzymes, SPF30 sunscreen, Intervention: none (only UV)
- Where
- Austria
- Volunteers
- 14 people
- Sponsor
- Medical University of Graz
Polymorphic Light Eruption
Vitamin D Supplementation in Polymorphic Light Eruption
Polymorphic light eruption (PLE) is a common photodermatosis with a high prevalence of approximately 11 to 21% in the population.
- Trial name
- VitD-PLE_2012 (NCT01595893)
- Testing
- Oral Vitamin D 3, Miglyol 812 N
- Where
- Austria
- Volunteers
- 8 people
- Sponsor
- Medical University of Graz
Polymorphic Light Eruption
Protective Effect Assessment of Foto Ultra Isdin Solar Allergy Fusion Fluid on the UVA Induced PLE
The primary objective of this Clinical Investigation was to assess the protective efficacy of a medical device (FOTO ULTRA ISDIN® SOLAR ALLERGY FUSION FLUID) against the polymorphic light eruption induced by the UVA.
- Trial name
- NCT05320315
- Testing
- Foto Ultra ISDIN® Solar Allergy Fusion Fluid
- Where
- France
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Centre de Pharmacologie Clinique Applique a la Dermatologie